Leaf in September 2008 and concentrates on biopharmaceutical investing. He is currently on the boards of directors of Array BioPharma (NASDAQ: ARRY), Neuronetics, Karus Therapeutics, Afferent, Calchan and Convergence, the latter three investments resulting from spin-outs from Roche (Afferent) and GSK (Calchan

investments in this sector will be larger. Recent medical device investments in the New Leaf portfolio that fit this later stage definition include: Neuronetics (NLV-II, commercial stage), CardioKinetix (NLV-IL, clinical development stage), and Interlace Medical (NLV-I, start-up focused on 510k product, acqui